Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) EBITDA (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBITDA for 5 consecutive years, with -$4.5 million as the latest value for Q4 2020.

  • On a quarterly basis, EBITDA rose 57.68% to -$4.5 million in Q4 2020 year-over-year; TTM through Dec 2020 was -$54.5 million, a 14.08% increase, with the full-year FY2024 number at -$35.5 million, down 12.71% from a year prior.
  • EBITDA was -$4.5 million for Q4 2020 at Forte Biosciences, up from -$5.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$352000.0 in Q3 2018 to a low of -$34.8 million in Q2 2020.
  • A 5-year average of -$12.2 million and a median of -$10.3 million in 2020 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 96.46% in 2018, then plummeted 5226.14% in 2019.
  • Forte Biosciences' EBITDA stood at -$8.0 million in 2016, then tumbled by 36.31% to -$10.9 million in 2017, then crashed by 80.37% to -$19.6 million in 2018, then soared by 45.85% to -$10.6 million in 2019, then soared by 57.68% to -$4.5 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's EBITDA are -$4.5 million (Q4 2020), -$5.0 million (Q3 2020), and -$34.8 million (Q2 2020).